Related Experiment Video
Updated: Jan 7, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Mutation patterns and prognostic potentiality of homologous recombination repair genes in gliomas
Hongmin Bai1, Yaqin Liu2, Cheng Ji1
1Department of Neurosurgery, General Hospital of Southern Theater Command/Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
Abstract:
Gliomas are primary malignant brain tumors with poor prognosis. Conventional therapies have achieved limited improvements, and there is an urgent need for new treatments. Homologous recombination repair (HRR) defects are observed in many types of cancer and confer increased sensitivity to platinum-based chemotherapies and poly-ADP ribose polymerase (PARP) inhibitors. To our knowledge, HRR mutations in gliomas have not been extensively reported. To this end, we analyzed alterations in 39 HRR related genes and divided patients with glioma into different groups according to HRR LOF mutation status. We then analyzed the differences in genetic mutation landscape, TMB, CNV burden, prognosis, and immune-related features between the HRR-LOF group and the NonHRR-LOF group. The results demonstrated that compared to the non-HRR-LOF group, the HRR-LOF group exhibited a higher mutation frequency of IDH1, increased TMB, and poor prognosis in IDH-mutant patients. In summary, gliomas patients with HRR LOF have relatively more unstable genomes and might benefit from the combination and sequential use of PARP inhibitors, radiotherapy, and immunotherapy.
Insights
Glioma patients with homologous recombination repair (HRR) loss-of-function mutations show increased genomic instability. These findings suggest potential benefits from PARP inhibitors, radiotherapy, and immunotherapy for HRR-deficient gliomas.
Area of Science:
- Neuro-oncology
- Cancer Genomics
- Molecular Biology
Background:
- Gliomas are aggressive brain tumors with limited treatment options.
- Homologous recombination repair (HRR) defects are linked to cancer therapies.
- HRR mutations in gliomas are underreported.
Purpose of the Study:
- To investigate HRR gene alterations in glioma.
- To compare genomic and prognostic features between HRR-LOF and non-HRR-LOF glioma groups.
- To identify potential therapeutic strategies for HRR-deficient gliomas.
Main Methods:
- Analysis of 39 HRR-related genes in glioma patients.
- Classification of patients based on HRR loss-of-function (LOF) mutation status.
- Comparative analysis of mutation landscape, TMB, CNV burden, prognosis, and immune features.
Main Results:
- The HRR-LOF group showed higher IDH1 mutation frequency and increased Tumor Mutational Burden (TMB) compared to the non-HRR-LOF group.
- HRR-LOF was associated with poor prognosis in IDH-mutant glioma patients.
- HRR-deficient gliomas exhibit more unstable genomes.
Conclusions:
- Glioma patients with HRR LOF mutations possess more unstable genomes.
- Combination or sequential therapy with PARP inhibitors, radiotherapy, and immunotherapy may benefit HRR-LOF glioma patients.
- Further research into HRR deficiency in gliomas is warranted for targeted treatment development.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Related Concept Videos
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
02:31Homologous Recombination
02:53Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...